| Literature DB >> 28342294 |
Jean-Pierre Jourdan1, Marc Since1, Laïla El Kihel1, Cédric Lecoutey1, Sophie Corvaisier1, Rémi Legay1, Jana Sopková-de Oliveira Santos1, Thierry Cresteil2, Aurélie Malzert-Fréon1, Christophe Rochais1, Patrick Dallemagne1.
Abstract
Herein we describe the drug design steps developed to increase the radical scavenging and β-amyloid aggregation inhibitory activities of a previously described series of benzylidenephenylpyrrolizinones. Among the newly synthesized derivatives, some benzylphenylpyrrolizinones exhibited interesting results in regard to those activities. Initial druggability parameters were measured, and suggest these compounds as a suitable starting point for potential alternatives in treating Alzheimer's disease.Entities:
Keywords: Alzheimer′s disease; MTDL; antioxidants; pyrrolizinones; β-amyloid
Mesh:
Substances:
Year: 2017 PMID: 28342294 DOI: 10.1002/cmdc.201700102
Source DB: PubMed Journal: ChemMedChem ISSN: 1860-7179 Impact factor: 3.466